Neuro-Behavioral Clinical Research Inc.

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease4 trials
• Depression3 trials
• Migraine2 trials
• Schizophrenia2 trials
• Bipolar disorder1 trial

Phase

• Phase 34 trials
• Phase 13 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Completed7 trials
• Terminated3 trials
• Active, not recruiting2 trials

Lead sponsor

• Pfizer2 trials
• Alar Pharmaceuticals Inc.1 trial
• atai Therapeutics, Inc.1 trial
• Biogen1 trial
• GAP Innovations, PBC1 trial
• and 6 more

Running trials

• Active, not recruiting

  PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

  NCT06750432· Phase 1· ProMis Neurosciences, Inc· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Pfizer· Source

Closed trials

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Multiple Ascending Dose Phase 1 Study of ALA-3000

  NCT06965569· Phase 1· Alar Pharmaceuticals Inc.· Source

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Recruiting

  Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

  NCT06584357· GAP Innovations, PBC· Source

  Contact: Amanda Ng, MA

• Completed

  Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

  NCT06126497· Phase 2· Suven Life Sciences Limited· Source

• Completed

  A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

  NCT05848700· Phase 1· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Terminated

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source